Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure  Up 2)
ConclusionsAdults and adolescents with moderate-to-severe atopic dermatitis treated with once-daily upadacitinib 15 or 30 mg experienced early improvements in itch, pain, other skin symptoms, sleep, quality of life, and mental health that were sustained through week  52.Clinical Trial RegistrationClinicalTrials.gov identifiers NCT03569293 (13 August 2018) and NCT03607422 (27 July 2018). (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - March 25, 2024 Category: Dermatology Source Type: research

Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada
ConclusionThis is the first study to highlight highly variable psoriasis incidence rates on a jurisdictional level and suggests that living environment, notably climate, vegetation, urbanization and neighborhood socioeconomic characteristics may have an association with psoriasis incidence. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - March 18, 2024 Category: Dermatology Source Type: research

Expert Panel Review of Skin and Hair Dermatophytoses in an Era of Antifungal Resistance
AbstractDermatophytoses are fungal infections of the skin, hair, and nails that affect approximately 25% of the global population. Occlusive clothing, living in a hot humid environment, poor hygiene, proximity to animals, and crowded living conditions are important risk factors. Dermatophyte infections are named for the anatomic area they infect, and include tinea corporis, cruris, capitis, barbae, faciei, pedis, and manuum. Tinea incognito describes steroid-modified tinea. In some patients, especially those who are immunosuppressed or who have a history of corticosteroid use, dermatophyte infections may spread to involve ...
Source: American Journal of Clinical Dermatology - March 18, 2024 Category: Dermatology Source Type: research

Management of Acne in Pregnancy
AbstractAcne is one of the most common dermatological conditions to affect women of childbearing age, so it is important to consider the safety of long-term acne treatments on women who could become pregnant. In this review article, we clarify what management options are available to treat acne during pregnancy. Topical treatments, typically first-line for acne, such as azelaic acid, clindamycin, erythromycin, metronidazole, benzoyl peroxide, salicylic acid, dapsone, and retinoids, were reviewed. Systemic treatments, such as zinc supplements, cephalexin, cefadroxil, amoxicillin, azithromycin, erythromycin, and corticostero...
Source: American Journal of Clinical Dermatology - March 7, 2024 Category: Dermatology Source Type: research

Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis
ConclusionAmong all available biologics and small-molecule inhibitors, secukinumab 300 mg and guselkumab 100 mg had the most favorable efficacy in treating PP and PPP, respectively. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - March 4, 2024 Category: Dermatology Source Type: research

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma
AbstractWith the development of effectiveBRAF-targeted and immune-checkpoint immunotherapies for metastatic melanoma, clinical trials are moving these treatments into earlier adjuvant and perioperative settings.BRAF-targeted therapy is a standard of care in resected stage III –IV melanoma, while anti-programmed death-1 (PD1) immunotherapy is now a standard of care option in resected stage IIB through IV disease. With both modalities, recurrence-free survival and distant-metastasis-free survival are improved by a relative 35–50%, yet no improvement in overall survival has been demonstrated. Neoadjuvant anti-PD1 therapy ...
Source: American Journal of Clinical Dermatology - February 26, 2024 Category: Dermatology Source Type: research

The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature
AbstractDermatologic adverse events resulting from oncologic therapy are common and negatively impact patients ’ quality of life. Dermatologic adverse events include toxicity of the skin, oral mucosa, nails, and hair and are seen with cytotoxic chemotherapy, targeted therapy, immunotherapy, and radiation therapy, with distinct patterns of dermatologic adverse events by drug class. Here, we review the liter ature on the impact of dermatologic adverse events on quality of life. Studies on quality of life in patients with cancer have relied on scales such as the Dermatologic Life Quality Index and Skindex to demonstrate the...
Source: American Journal of Clinical Dermatology - February 16, 2024 Category: Dermatology Source Type: research

Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review
AbstractField cancerization theory highlights that the skin surrounding actinic keratoses (AK) is also at increased risk for possible malignant transformation; thus, field-directed treatments may both reduce the risk of AK recurrence and potentially reduce the risk of development of cutaneous squamous cell carcinoma (cSCC). Photodynamic therapy (PDT) with either aminolevulinic acid (ALA) or methylaminolevulinate (MAL), as well as topical treatments such as 5-fluorouracil (5-FU), diclofenac gel, piroxicam, imiquimod, and ingenol mebutate, have all shown higher efficacy than vehicle treatments. PDT is widely recognized for i...
Source: American Journal of Clinical Dermatology - February 13, 2024 Category: Dermatology Source Type: research

Correction to: OX40 in the Pathogenesis of Atopic Dermatitis —A New Therapeutic Target
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - February 10, 2024 Category: Dermatology Source Type: research

Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study
ConclusionThis is the first study to identify correlations between HS with melanoma and basal cell carcinoma (BCC) among Black patients as well as MS and lupus in all patients with HS. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - February 9, 2024 Category: Dermatology Source Type: research

Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma
AbstractThere have been many recent advances in melanoma therapy. While 50% of melanomas have a BRAF mutation and are a target for BRAF inhibitors, the remaining 50% are BRAF wild-type. Immune checkpoint inhibitors targeting PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and lymphocyte activated gene-3 (Lag-3) are all approved for the treatment of patients with advanced BRAF wild-type melanoma; however, treatment of this patient population following initial immune checkpoint blockade is a current therapeutic challenge given the lack of other efficacious options. Here, we briefly review available US FDA-approved ...
Source: American Journal of Clinical Dermatology - February 8, 2024 Category: Dermatology Source Type: research

Autoimmune and Cutaneous Inflammatory Comorbidities in Adult-Onset Morphea in the All of Us Research Program
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - February 2, 2024 Category: Dermatology Source Type: research

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study
ConclusionsThe risk of tuberculosis reactivation in patients with psoriasis and LTBI does not seem to increase with IL-17 or IL-23 inhibitors. IL-17 or IL-23 inhibitors should be preferred over TNF antagonists when concerns regarding tuberculosis reactivation exists. In patients with LTBI considered at high risk for developing complications related to chemoprophylaxis, this preventive strategy may be waived before initiating treatment with IL-17 inhibitors and especially IL-23 inhibitors. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - January 24, 2024 Category: Dermatology Source Type: research

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
ConclusionsRitlecitinib is well tolerated with an acceptable safety profile up to 24 months in patients aged ≥ 12 years with AA (video abstract and graphical plain language summary available).Trial RegistriesClinicalTrials.gov: NCT02974868 (date of registration: 11/29/2016), NCT04517864 (08/18/2020), NCT03732807 (11/07/2018), and NCT04006457 (07/05/2019). (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - January 23, 2024 Category: Dermatology Source Type: research

The Skin Microbiome and its Significance for Dermatologists
AbstractThe skin is a physical and immunological barrier to the external environment. Its large surface area is colonized by diverse communities of microorganisms, including bacteria, viruses, fungi, andDemodex species mites. These microorganisms and their genetic material together create the skin microbiome. Physiologic and anatomic properties of skin sites create biogeographical habitats (dry, moist, and sebaceous) where distinct microbiota communities reside. Although, in general, the composition of these habitats is maintained from person to person, the skin microbiome of an individual also has unique microbial feature...
Source: American Journal of Clinical Dermatology - January 22, 2024 Category: Dermatology Source Type: research